Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 8, 2013, Pages 918-921

  Kitley, Joanna ^a   Elsone, Liene ^b   George, Jithin ^a   Waters, Patrick ^a   Woodhall, Mark ^a   Vincent, Angela ^a   Jacob, Anu ^b   Leite, Maria Isabel ^a   Palace, Jackie ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELOOPTIC NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

EID: 84879895266     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304774     Document Type: Article

References (21)

1. Mandler R, Ahmed W, Dencoff J. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-20. (Pubitemid 28473439)
2. Bichuetti D, de Oliveira E, Oliveira D, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010;67:1131-6.
3. Costanzi C, Matiello M, Lucchinetti C, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77:659-66.
4. Jacob A, Matiello M, Weinshenker B, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-33.
5. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al . Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-63. (Pubitemid 44036296)
6. Kim S, Kim W, Park M, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011;68:473-9.
7. Cabre P, Olindro S, Marignier R, et al. Effi cacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2012. Published Online First: 8 November 2012 doi:10.1136/jnnp-2012-303121.
8. Cree B, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-2.
9. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic 's disease). Neurol Sci 2007;28:209-11. (Pubitemid 47263843)
10. Jacob A, Weinshenker B, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-8.
11. Bedi G, Brown A, Delgado S, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17:1225-30.
12. Pellkofer H, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310-5.
13. Heckmann J, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurology 2011;11:97.
14. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;65:913-9. (Pubitemid 352008474)
15. Minagar A, Sheremata WA. Treatment of Devic' s disease with methotrexate and prednisone. Int J MS Care 2000;2:43-9.
16. McKeon A, Lennon V, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
17. Sahraian M, Moinfar Z, Khorramnia S, et al. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 2010;17:794-9.
18. Patel V, MacDonald J, McDonald J, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;4:CD006884.
19. Katchamart W, Trudeau J, Phumethum V, et al. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010;4:CD008495.
20. Khan N, Abbas A, Whang N, et al. Incidence of liver toxicity in infl ammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2012;18:359-67.
21. Saag H, Gee Teng G, Patkar N, et al. American College of Rheumatology 2008 Recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)